Jason Zemansky
Stock Analyst at B of A Securities
(3.91)
# 645
Out of 5,113 analysts
48
Total ratings
81.82%
Success rate
51.94%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Maintains: Neutral | $18 → $19 | $20.26 | -6.22% | 3 | Nov 28, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $17 → $26 | $21.98 | +18.29% | 6 | Nov 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $10 → $8 | $3.23 | +147.68% | 3 | Nov 18, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $8 → $7 | $0.69 | +919.22% | 6 | Nov 18, 2025 | |
| INSM Insmed | Maintains: Buy | $142 → $187 | $174.84 | +6.95% | 11 | Oct 27, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $62.72 | -10.71% | 5 | Oct 2, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $34.51 | -10.17% | 4 | Apr 1, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $9.84 | +194.72% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $20.77 | +49.25% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $3.93 | -36.39% | 5 | Jun 20, 2024 |
Keros Therapeutics
Nov 28, 2025
Maintains: Neutral
Price Target: $18 → $19
Current: $20.26
Upside: -6.22%
Arcus Biosciences
Nov 28, 2025
Maintains: Neutral
Price Target: $17 → $26
Current: $21.98
Upside: +18.29%
Rocket Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $3.23
Upside: +147.68%
Werewolf Therapeutics
Nov 18, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $0.69
Upside: +919.22%
Insmed
Oct 27, 2025
Maintains: Buy
Price Target: $142 → $187
Current: $174.84
Upside: +6.95%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $62.72
Upside: -10.71%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $34.51
Upside: -10.17%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $9.84
Upside: +194.72%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $20.77
Upside: +49.25%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $3.93
Upside: -36.39%